The Conversation (0)
Advanced Proteome Therapeutics Corporation (TSXV:APC) reported that in the first detailed studies with collaborators, the lead member of the first series exhibited stunning activity in retarding tumor growth in mice. Advanced Proteome Therapeutics has been preparing several series of potential anticancer agents.
Advanced Proteome Therapeutics Corporation (TSXV:APC) reported that in the first detailed studies with collaborators, the lead member of the first series exhibited stunning activity in retarding tumor growth in mice. Advanced Proteome Therapeutics has been preparing several series of potential anticancer agents.
As quoted in the press release:
We are now especially pleased to report that in the first detailed studies with our collaborators, the lead member of the first series has exhibited stunning activity in retarding tumor growth in mice, substantially superior to the parent protein. The experiments were performed by varying the concentration of the modified protein, which gave classical dose-dependent plots showing retardation of tumor growth.
Click here to read the Advanced Proteome Therapeutics Corporation (TSXV:APC) press release
